Posters

Efficiency of Anti-VEGF in the treatment of corneal neovascularization present in ocular rosacea

Poster Details

First Author: A.Faiza MOROCCO

Co Author(s): J. Aitelhaj   A. Mchachi   L. Benhmidoune   A. Chakib   R. Rachid   M. Elbelhadji     

Abstract Details

Purpose:

The diagnosis of ocular rosacea can be very challenging if accompanying roseatic skin changes are subtle or inexistent .It is often associated with chalazions and meibomites. Corneal opacification and neovascularization are possible  complications of disease. Subconjunctival administration of ANTI VEGF is a reference treatment. Efficiency of ANTI VEGF in the treatment of corneal neovascularization present in ocular rosacea

Setting:

Unity of ophthalmology adult, hospital 20 aout1953, Hospital university ibn Rochd, the Faculty of Medicine and Pharmacy, Hassan II university, Casablanca

Methods:

We report one case of 22 years old woman who has corneal opacification with rosacea.and review of medical literature.

Results:

A young woman,with recurrent red eyes and photophobia,presented with decreased visual acuity.On our clinical examination,the patient’s visual acuity was hand motion on the right eye(RE)and 10/10 on the left eye(LE),with typical clinical signs of rosacea and prominent lower vascular involvement extended to the center of the cornea with central and inferior corneal opacity on RE.We found also the same symptomatology on the left eye but less obvious.The patient was treated with oral cyclines,topical corticosteroids and artificial tears without preservatives.She also received two subconjunctival injections of anti-VEGF on RE(Bevacizumab)at 1month intervals.The patient responded well to this therapy 6 months later.

Conclusions:

The diagnosis of ocular rosacea is not always obvious and requires a good analysis of functional and clinical signs.Ocular rosacea has a chronic evolution and requires prolonged or even permanent treatment. Adjuvanted anti-vegf treatment remains a remedy for corneal complications. Nevertheless, the recent development of anti-angiogenic therapies targeting the intracellular pathways of angiogenesis (Sirna, oligonucleotide antisens) is a promising alternative.

Financial Disclosure:

None